Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

InMed Pharmaceuticals (INM) Depreciation Expense (2022 - 2025)

InMed Pharmaceuticals (INM) has 3 years of Depreciation Expense data on record, last reported at $12206.0 in Q2 2025.

  • For Q2 2025, Depreciation Expense rose 124.37% year-over-year to $12206.0; the TTM value through Jun 2025 reached $50204.0, up 5.16%, while the annual FY2025 figure was $50204.0, 5.16% up from the prior year.
  • Depreciation Expense reached $12206.0 in Q2 2025 per INM's latest filing, roughly flat from $12203.0 in the prior quarter.
  • Across five years, Depreciation Expense topped out at $14242.0 in Q4 2023 and bottomed at $5440.0 in Q2 2024.
  • Average Depreciation Expense over 3 years is $12144.7, with a median of $12562.5 recorded in 2023.
  • Peak YoY movement for Depreciation Expense: tumbled 57.88% in 2024, then soared 124.37% in 2025.
  • A 3-year view of Depreciation Expense shows it stood at $14242.0 in 2023, then decreased by 14.27% to $12209.0 in 2024, then decreased by 0.02% to $12206.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation Expense were $12206.0 in Q2 2025, $12203.0 in Q1 2025, and $12209.0 in Q4 2024.